Oxazolam

Alloplastic materials based on biopolymers such as silk fibroin (SF) have provided the synthesis of excellent biomaterials for bone repair. The aim of the present study was to produce SF membranes associated to hydroxyapatite (HA) and evaluate their physicochemical characteristics and the toxicity potential. After obtaining the SF, the HPLC was executed to verify the elimitation of serecin, a toxic protein of the silk, and the cytotoxicity assay was assessed in the subtances from the SF processing. SF and SF-HA membranes were evaluated by SEM, EDS, FTIR, mechanical properties and toxicity (cytotoxicity, genotoxicity and mutagenic effects). The serecin was elimined in the SF process, and its cytotoxicity was confirmed. SF and SF-HA membranes presented interesting results based on the physicochemical characterization. SF membrane showed cytotoxic, genotoxic and mutagenic effects. In conclusion, SF and SF-HA membranes presented adequate mechanical resistance to act respectively as wound healing or bone filling materials, and they were hydrophilic. SF-HA membrane did not present any toxic potential and allowed cell adhesion and proliferation. The unexpected cyto/genotoxicity and mutagenic effect of SF evidenced the importance of investigating the toxic potential of biomaterials, mainly those in contact with human body for prolonged time.

Introduction: Benzodiazepine anxiolytics are believed to cause urination disorders due to their anticholinergic effects. Objective: This study was carried out to investigate the potential inhibitory effects of 15 clinically available anxiolytics in Japan on acetylcholine (ACh)-induced contractions in rat detrusor smooth muscle (DSM) to predict whether these anxiolytics could induce urination disorders. Methods: ­Effects of anxiolytics on contractions induced by ACh and 80 mmol/L KCl solution in rat DSM and effects of anxiolytics on specific binding of [N-methyl-³H]scopolamine ([³H]NMS) in mouse cerebral cortex were investigated. Results and Conclusions: ACh-induced contractions in rat DSM were inhibited by clotiazepam and diazepam (benzodiazepine anxiolytics) at concentrations that were clinically relevant. These contractions were also significantly inhibited by paroxetine, escitalopram (selective serotonin reuptake inhibitors ­[SSRIs]), and hydroxyzine (a histamine H₁ receptor antagonist), albeit at concentrations that substantially exceeded clinically achievable blood levels. At a concentration of 10^–5 mol/L, paroxetine, escitalopram, and hydroxyzine inhibited 80 mmol/L high-KCl solution-induced rat DSM contractions but not clotiazepam and diazepam. Paroxetine, escitalopram, and hydroxyzine also inhibited specific binding of [³H]NMS in mouse cerebral cortex but clotiazepam and diazepam did not. In contrast to the effects of the abovementioned anxiolytics, ACh-induced contractions were not significantly affected by tofisopam, alprazolam, lorazepam, bromazepam, oxazolam, chlordiazepoxide, clonazepam, ethyl loflazepate (benzodiazepine anxiolytics), fluvoxamine (an SSRI), or tandospirone (a serotonin 5-HT_1A receptor agonist). These findings suggest that most clinically used anxiolytics are not likely to result in anticholinergic-induced urination disorders within their clinically achievable blood concentration ranges. However, clotiazepam and diazepam may induce urination disorders within their clinical dose ranges via nonanticholinergic inhibition of DSM contractility.